EGM
RNAC icon

Engineers Gate Manager’s Cartesian Therapeutics RNAC Stock Holding History

Engineers Gate Manager’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-423
Closed -$8.25K – 2187
2024
Q1 		$8.25K Hold
423
– – ﹤0.01% 1858
2023
Q4 		$8.75K Buy
+423
New +$12.6K ﹤0.01% 1925
2023
Q2 		– Sell
-607
Closed -$25.3K – 1985
2023
Q1 		$25.3K Sell
607
-6
-1% -$282 ﹤0.01% 1582
2022
Q4 		$20.8K Sell
613
-23
-4% -$979 ﹤0.01% 1600
2022
Q3 		$31K Sell
636
-1,507
-70% -$82.8K ﹤0.01% 1528
2022
Q2 		$84K Buy
2,143
+1,665
+348% +$49.4K ﹤0.01% 1757
2022
Q1 		$18K Buy
+478
New +$29.9K ﹤0.01% 1778

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Engineers Gate Manager's RNAC Position: Q2 2024 in Review

Engineers Gate Manager sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 423 shares — an estimated $8.25K sold.

Engineers Gate Manager first reported a position in RNAC in Q1 2022 and held it in 7 quarters. The position peaked at $84K in Q2 2022. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Engineers Gate Manager reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 423 Cartesian Therapeutics shares in Q2 2024, an estimated $8.25K.
  • Engineers Gate Manager first reported a position in Cartesian Therapeutics in Q1 2022 and held it in 7 quarters.
  • Engineers Gate Manager's Cartesian Therapeutics position peaked at $84K in Q2 2022.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Engineers Gate Manager's 13F filing for Q2 2024, filed 14 Aug 2024.